When given before a stem cell transplant, busulfan plus melphalan, improved progression-free survival in patients with myeloma, but came with some extra adverse events.
A two-drug regimen of busulfan plus melphalan improved progression-free survival (PFS) in patients with myeloma who were undergoing an autologous hematopoietic stem cell transplant compared to those who received melphalan alone. However, this combination came with an extra dose of side effects, according to research presented by Lori Williams, PhD, APRN, AOCN, OCN, at the 2018 Oncology Nursing Society Annual Congress.
The two-drug regimens were given before transplant, and then patients were tracked for PFS after. Patients in the busulfan/melphalan arm had an average PFS of 64.7 months, compared to 34.4 months for patients who only received melphalan.
But, for the first 4 weeks after transplant, patients on the combination reported a higher symptom burden, that included sore mouth, sore throat, and mouth pain. After the first month or so, the number of patient-reported adverse events decreased for both groups, but still remained higher for the combination arm.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.